Statin Utilization and Recommendations among HIV- and HCV-infected Veterans: A Cohort Study

Meredith E. Clement, Lawrence P. Park, Ann Marie Navar, Nwora Lance Okeke, Michael J. Pencina, Pamela S. Douglas, Susanna Naggie

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Background. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are associated with increased risk of cardiovascular disease (CVD). The potential impact of recently updated cholesterol guidelines on treatment of HIV- and HCV-infected veterans is unknown. Methods. We performed a retrospective cohort study to assess statin use and recommendations among 13 579 HIV-infected, 169 767 HCV-infected, and 6628 HIV/HCV-coinfected male veterans aged 40-75 years. Prior 2004 Adult Treatment Panel (ATP-III) guidelines were compared with current 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines and 2014 US Department of Veterans Affairs (VA)/US Department of Defense (DoD) joint clinical practice guidelines using laboratory, medication, and comorbidity data from the VA Clinical Case Registry from 2008 through 2010. Results. Using risk criteria delineated by the ATP-III guidelines, 50.6% of HIV-infected, 45.9% of HCV-infected, and 33.8% of HIV/HCV-coinfected veterans had an indication for statin therapy. However, among those eligible, 22.7%, 30.5%, and 31.5%, respectively, were not receiving ATP-III recommended statin therapy. When current cholesterol guidelines were applied by VA/DoD and ACC/AHA criteria, increases in recommendations for statins were found in all groups (57.3% and 66.1% of HIV-infected, 64.4% and 73.7% of HCV-infected, 49.1% and 58.5% of HIV/HCV-coinfected veterans recommended). Conclusions. Statins were underutilized among veterans infected with HIV, HCV, and HIV/HCV according to previous ATP-III guidelines. Current VA/DoD and ACC/AHA guidelines substantially expand statin recommendations and widen the gap of statin underutilization in all groups. These gaps in care present an opportunity to improve CVD prevention efforts in these at-risk populations.

Original languageEnglish (US)
Pages (from-to)407-413
Number of pages7
JournalClinical Infectious Diseases
Issue number3
StatePublished - Aug 1 2016
Externally publishedYes


  • cardiovascular disease
  • hepatitis C virus
  • human immunodeficiency virus
  • hydroxymethylglutaryl-CoA reductase inhibitors
  • statins

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Statin Utilization and Recommendations among HIV- and HCV-infected Veterans: A Cohort Study'. Together they form a unique fingerprint.

Cite this